G1 Therapeutics, Inc. (Nasdaq: GTHX) to Ring The N

ADVISORY, Aug. 01, 2017 (GLOBE NEWSWIRE) --

What:  G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Mark Velleca, Chief Executive Officer , will ring the Closing Bell. 

Where: Nasdaq MarketSite – 4 Times Square – 43 ^rd & Broadway – Broadcast Studio

When: Wednesday, August 2, 2017 – 3:45 p.m. to 4:00 p.m. ET

G1 Therapeutics, Inc. Contact:

Investors: Robert Uhl Westwicke Partners (858) 356-5932 robert.uhl@westwicke.com

Media: Laura Bagby                      6 Degrees Communications (312) 448-8098 lbagby@6degreespr.com

Nasdaq MarketSite: Emily Pan (646) 441-5120 emily.pan@nasdaq.com

Feed Information: Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/NASDAQ .

For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page: http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page: http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page: http://nasdaq.tumblr.com/

Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About G1 Therapeutics, Inc. G1 Therapeutics (GTHX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. In addition, G1 is advancing G1T48, a potential first/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.

G1 is based in Research Triangle Park, NC. For additional information about G1, please visit www.g1therapeutics.com .

About Nasdaq: Nasdaq (Nasdaq: NDAQ ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com

-NDAQA-